Code and Payment Changes in October Update to OPPS

Code and Payment Changes in October Update to OPPS

The October 2016 update to the Outpatient Prospective Payment System (OPPS) includes one new HCPCS Level II code, two deleted HCPCS Level II codes; ambulatory payment classification (APC) and status indicator (SI) changes to several drug codes; and other changes to various payment policies.

New Ultrasound Code

HCPCS Level II code C9744 Ultrasound, abdominal, with contrast is effective Oct. 1, 2016. This new code has been assigned an OPPS SI of S and an OPPS APC of 5571.

CPB : Online Medical Billing Course

Deleted G Codes

Effective Sept. 30, 2016, HCPCS Level II codes G0436 Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes and G0437 Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes are deleted. For claims with dates of service on or after Oct. 1, 2016, report, instead, CPT codes 99406 Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes and 99407 Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes. The pricing information is the same.

Non-therapy Outpatient Department Services

Effective for claims received on or after Oct. 1, 2016, with dates of service on or after Jan. 1, 2015, providers may report non-therapy outpatient department services that are adjunctive to a Comprehensive APC procedure (SI=J1) or the specific combination of services assigned to the C-APC 8011 (SI=J2) in one of two ways:

  1. With revenue code 0940 Other therapeutic services; or
  2. With the appropriate occurrence codes, CPT codes, modifiers, revenue codes, and functional reporting requirements.

Updates to Drugs, Biologicals, and Radiopharmaceuticals

Four drugs/biologicals granted OPPS pass-through status (SI=G) effective Oct. 1, 2016, are:

C9139             Injection, Factor IX, albumin fusion protein (recombinant), Idelvion, 1 i.u.
C9481             Injection, reslizumab, 1 mg
C9482             Injection, sotalol hydrochloride, 1 mg
C9483             Injection, atezolizumab, 10 mg

Effective July 1, 2016, Q5102 Injection, Infliximab, Biosimilar, 10 mg has been reassigned to SI E (Not paid under OPPS or any other Medicare payment system).

Changes to OPPS Pricer Logic

OPPS drug pricing will now apply the average sales price (ASP) fee schedule amounts from the Fiscal Intermediary Shared System (FISS) and not the OPPS Pricer.

Deleted Codes Due to Internal Requests

Unrelated to the OPPS quarterly update, codes to be discontinued effective Dec. 31, 2016, are:

A9544 Iodine i-131 tositumomab, diagnostic, per study dose
A9545 Iodine i-131 tositumomab, therapeutic, per treatment dose
Rationale: The products have been discontinued by the manufacturer, and are no longer sold.

J0760 Injection, Colchicine, per 1 mg
Rationale: The FDA has removed marketing clearance for this drug.

Q4219 Unite Biomatrix, per square centimeter
Rationale: This product was discontinued by the manufacturer in 2012, and is no longer sold.


Resources:

MLN Matters Number MM9768, Aug. 26, 2016

CMS, Internal HCPCS Decisions 2016-2017

2017-code-book-bundles-728x90-01

Renee Dustman

Renee Dustman

Renee Dustman is executive editor at AAPC. She has a Bachelor of Science degree in Journalism and a long history of writing just about anything for just about every kind of publication there is or ever has been. She’s also worked in production management for print media, and continues to dabble in graphic design.
Renee Dustman

About Has 423 Posts

Renee Dustman is executive editor at AAPC. She has a Bachelor of Science degree in Journalism and a long history of writing just about anything for just about every kind of publication there is or ever has been. She’s also worked in production management for print media, and continues to dabble in graphic design.

One Response to “Code and Payment Changes in October Update to OPPS”

  1. Jenna M. Shaffer says:

    Awesome article. Thanks!

Leave a Reply

Your email address will not be published. Required fields are marked *